Bayer lymphoma candidate secures FDA priority review designation
The priority review has been specifically designated for treatment of FL patients whose disease had relapsed or is in the refractory stage and had also received at least
Plus Therapeutics has entered into a manufacturing services agreement (MSA) with SpectronRx to produce the radiotherapy, Rhenium (186Re) Obisbemeda, for central nervous system (CNS) cancers.
Tenapanor is Ardelyx's investigational, minimally systemic, small-molecule NHE3 inhibitor. The T3MPO-1 trial achieved statistical significance for the primary endpoint and seven of eight secondary endpoints. The primary endpoint,